Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New medical food tolerability study for rare metabolic conditions

NCT ID NCT05051657

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special medical food called Express Plus is acceptable for children and adults with certain inherited metabolic disorders like PKU and maple syrup urine disease. Over 28 days, 28 participants tried the product and reported how well they liked it, how easy it was to use, and any stomach issues. The goal was to see if this food could help people stick to their prescribed diet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Jun 2021

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of PKU or associated disorder for example, Tetrahydrobiopterin (BH4) deficiency, requiring a low protein diet and Phe-free L-amino acid supplements (protein substitute). * Established on PKU express or an equivalent protein substitute * In the opinion of the study investigator, the participant is able to take the study product and meets at least one of the following criteria: 1. taking an age inappropriate protein substitute 2. struggling with adherence to current protein substitute 3. delayed in transitioning * Aged 3 years and above * Willingly given, written, informed consent from patient or parent/guardian. * Willingly given, written assent (if appropriate). Exclusion Criteria: * Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and protein substitute. * Patients who are tube-fed. * Individuals, who in the opinion of the investigator, are unable to comply with the requirements of the protocol. * Any co-morbidity/condition which in the opinion of the Investigator, would preclude participation in the study. * Patients who are currently participating in, plan to participate in, or have participated in an interventional investigational drug, food or medical device trial within 30 days prior to screening. * Use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file). * Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period. (N.B.: Women who become pregnant unexpectedly during this study may, in consultation with their doctor, continue on the study's dietary product if they wish but will not have any investigations that would not normally be carried out during pregnancy.) * Those with allergies to fish, milk or soya.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glutaric acidemia I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Birmingham Women's and Children's Hospital

    Birmingham, B15 2TG, United Kingdom

  • Bristol Royal Hospital for Children

    Bristol, BS2 8BJ, United Kingdom

  • Great Ormond Street Hospital for Children

    London, WC1N 3JH, United Kingdom

  • Greater Glasgow and Clyde NHS Foundation Trust

    Glasgow, G12 0XH, United Kingdom

  • Nottingham Children's Hospital

    Nottingham, NG7 2UH, United Kingdom

  • Royal Belfast Hospital for Sick Children

    Belfast, BT12 6BA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.